US EditionGC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
The AI-driven cfDNA blood test showed 90.4% sensitivity and 94.7% specificity in detecting colorectal cancer and advanced adenomas, offering a less invasive screening option.
- Publication in The American Journal of Gastroenterology shows GC Genome's AI-based fragmentomics technology was validated for early colorectal cancer detection, with 90.4% sensitivity and 94.7% specificity.
- As a screening alternative, the study suggests a convenient option to colonoscopy and fecal-based screening tests for earlier detection of colorectal cancer and advanced adenomas using a 10 mL blood sample.
- In the trial, researchers enrolled 1,677 study participants, including 302 with CRC and 108 with AA, achieving CRC sensitivity of 90.4% and specificity of 94.7%.
- It was reported that GC Genome will expand global clinical collaborations and screening applications, including a future ai-CANCERCH upgrade from six to ten cancers.
- With CAP-accredited labs, GC Genome is positioned to scale testing, leveraging R&D emphasis and genetic diagnosis services for oncology, pre&neonatal, and rare diseases to expand global clinical capacity.
58 Articles
58 Articles
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
YONGIN, South Korea, Nov. 27, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon,...
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
YONGIN, South Korea, Nov. 27, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik's team at Asan Medical Center has been published in The American Journal of…
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
YONGIN, South Korea, Nov. 27, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik's team at Asan Medical Center has been published in The American Journal of…
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
YONGIN, South Korea, Nov. 27, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik's team at Asan Medical Center has been published in The American Journal of…
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
YONGIN, South Korea, Nov. 27, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik's team at Asan Medical Center has been published in The American Journal of…
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
YONGIN, South Korea, Nov. 27, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik's team at Asan Medical Center has been published in The American Journal of…
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
